Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BICYCLE THERAPEUTICS PLC Director's Dealing 2021

Aug 25, 2021

32777_dirs_2021-08-25_b0d5cb06-9d01-4d1e-8377-e2f6c2124ea7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BICYCLE THERAPEUTICS plc (BCYC)
CIK: 0001761612
Period of Report: 2021-08-23

Reporting Person: Kalowski Lee (President and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-23 Ordinary Shares M 7500 $1.60 Acquired 7500 Direct
2021-08-23 Ordinary Shares S 7500 $33.02 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-08-23 Stock Option (Right to Buy) $1.60 M 7500 Disposed 2027-07-23 Ordinary Shares (7500) Direct

Footnotes

F1: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.

F2: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.366815 to GBP 1.00 as of August 23, 2021.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to
$33.056 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this
footnote.

F4: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36
equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the
grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting
milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date.